S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
NCT01854749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57
Last updated 2016-02-23
Summary
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
Conditions
Interventions
- DRUG
-
S1 combined with cisplatin
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2015-12-31
Countries
- China
Study Locations
More Related Trials
-
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
NCT03823118 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
NCT06657690 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
NCT05773092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
NCT03457337 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
NCT04237805 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
NCT03940976 ·Status: UNKNOWN ·Phase: PHASE2
-
Liposomal Irinotecan and Apatinib in ES-SCLC
NCT06749691 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
NCT02037997 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
NCT05255406 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
NCT05055947 ·Status: COMPLETED
-
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT05435248 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
NCT01874678 ·Status: COMPLETED ·Phase: NA
-
Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer
NCT03154242 ·Status: UNKNOWN
-
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
NCT05957510 ·Status: RECRUITING ·Phase: PHASE2
-
A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure
NCT02618590 ·Status: UNKNOWN
-
The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer
NCT01797913 ·Status: COMPLETED ·Phase: PHASE2
-
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
NCT00005989 ·Status: COMPLETED ·Phase: PHASE2
-
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
NCT05847764 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT06147570 ·Status: RECRUITING ·Phase: PHASE2
-
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
NCT01392235 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
NCT04659785 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
NCT03100955 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
NCT04501029 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
NCT05435274 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2